Health Condition 1: M722- Plantar fascial fibromatosis
Conditions
Interventions
Intervention1: Platelet Rich Plasma: Injection of 1.5 ml of autologous PRP will be injected using a peppering technique, involving 3-4 penetrations of the fascia but only a single skin portal.
Interve
Sponsors
PG Research grant
Eligibility
Inclusion criteria
Inclusion criteria: Patient with unilateral or bilateral heel pain diagnosed to have Chronic Plantar fasciitis using either of the two following diagnostic criterias 2.1) Clinical criteria 1) Patients describing heel pain that is worse in the morning or after a period of inactivity. 2)Patients complaining of heel pain initially lessens out and then gradually increasing towards the end of day. 3)Patient has a local point tenderness near the origin of the plantar fascia at the medial tuberosity of the calcaneum. 2.2) USG criteria: Ultrasound examination showing plantar fascia thickness greater than or equal to 4 mm or difference in plantar fascia thickness greater than or equal to 1 mm in symptomatic heel in comparison to asymptomatic heel at inferior border of the calcaneus. 3. Patient have significant pain(VAS score greater than 3) even after conservative managements for more than 3 weeks. 4. In bilateral cases, foot with more clinical severity will be taken into the study. 5. Patient has to be literate (able to read and understand) in either English or Hindi language
Exclusion criteria
Exclusion criteria: Received local steroid injection within 6 months. 2. History of anemia (Hb lesser than 10g/dL) or bleeding disorders. 3. Previous surgery for plantar fasciitis. 4. Achilles tendon pathology. 5. Diagnosed case of local malignancy. 6. Diagnosed case of rheumatological diseases. 7. Patients on anticoagulation therapy. 8. Diagnosis of vascular insufficiency or neuropathy related heel pain (radiculopathy, tarsal tunnel syndrome) and other causes of heel pain. 9. Any local trauma or infection. 10. Anatomical deformities of foot like pes planus and pes cavus. 11. Patient with uncontrolled diabetes and hypertension. 12. Patient not willing for the participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure will be the difference in pain from the baseline in VAS scales assessed at 2 weeks, 4 weeks, 8 weeks and 12 weeks from the date of interventionTimepoint: The primary outcome measure will be the difference in pain from the baseline in VAS scales assessed at 2 weeks, 4 weeks, 8 weeks and 12 weeks from the date of intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Difference in pain and functional limitation from the baseline in the Foot function Index scale to be analyzed at 2 weeks, 4 weeks, 8 weeks and 12 weeks from the date of interventionTimepoint: 1) Difference in pain and functional limitation from the baseline in the Foot function Index scale to be analyzed at 2 weeks, 4 weeks, 8 weeks and 12 weeks from the date of intervention;2) The difference in plantar fascia thickness from the baseline measured using ultrasound calipers at 12 weeks post intervention.Timepoint: 2) The difference in plantar fascia thickness from the baseline measured using ultrasound calipers at 12 weeks post intervention. | — |
Countries
India
Contacts
Public ContactAnanthakrishna J
All India Institute of Medical Sciences, New Delhi
Outcome results
None listed